Secondary Tumors

Slide 1 · Secondary Malignant Tumors

of the Urinary Bladder

Direct extension • Systemic lymphoma • Rare distant metastases

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Distinguish secondary involvement from a primary bladder neoplasm.

Recognize direct extension, systemic lymphoma and rare distant metastasis.

Integrate morphology, clinical history, imaging and focused immunophenotyping.

Avoid applying primary bladder staging to a tumor originating elsewhere.

Slide 3 · What “secondary bladder tumor” means

Malignancy involving the bladder but originating outside the bladder.

Origin may be a neighboring pelvic organ or a distant anatomic site.

Bladder involvement does not automatically mean a primary urothelial cancer.

Site of involvement ≠ site of origin

Slide 4 · Three routes to the urinary bladder

DIRECT EXTENSION

SYSTEMIC LYMPHOMA

DISTANT SOLID-TUMOR SPREAD

Direct extension from an adjacent primary malignancy: Predominant pattern.

Bladder involvement by lymphoma as part of systemic disease.

Distant spread of solid tumors: Possible but very uncommon.

Slide 5 · Direct extension is the main mechanism

Cervix, uterus, prostate and rectum as the principal adjacent sources.

Contiguity is the defining spatial relationship.

Recognition changes the assigned primary site and diagnostic communication.

Cervix / uterus

Prostate

Rectum

BLADDER

Slide 6 · A pelvic-organ interface

A malignant process crosses from its organ of origin into the bladder region.

Tumor at the interface may be sampled as a “bladder mass.”

A bladder biopsy alone may not reveal the direction of spread.

Original organ

Bladder wall

Contiguous tumor

Schematic of direct extension

Slide 7 · Why the clinical history matters

Prior pelvic carcinoma increases suspicion for secondary bladder involvement.

Review histologic type, treatment history and current anatomic imaging.

A new bladder lesion can still be an independent primary: Compare evidence.

PAST / PRESENT MALIGNANCY

BLADDER LESION

INTEGRATED ORIGIN ASSESSMENT

Slide 8 · How uncommon are secondary tumors?

Secondary neoplasms constitute a small minority of bladder malignancies.

Reported percentages vary with specimen selection and case definitions.

Do not substitute a series-specific estimate for population incidence.

Rare as a group; Direct spread predominates within the group

Slide 9 · Contiguous spread versus distant metastasis

Question

Direct extension

Distant metastasis

Anatomic continuity

Expected

Absent or not demonstrable

Usual context

Locally advanced adjacent primary

Systemically disseminated malignancy

Principal proof

Imaging / operative continuity

History, imaging, histology ± IHC

Key caution

Not an independent bladder primary

Not inferred from morphology alone

Slide 10 · Conceptual sequence of direct invasion

Original malignancy enlarges toward an adjacent tissue interface.

Tumor reaches the bladder wall and may subsequently involve its lining.

Depth and direction must be established from the actual specimen and imaging.

ADJACENT PRIMARY

INTERORGAN TISSUES

BLADDER WALL

Slide 11 · Wall layers: A useful orientation

Urothelium and lamina propria form the luminal side.

Muscularis propria lies deeper; Perivesical tissues are external.

Layer involvement alone does not prove whether a tumor began in the bladder.

Urothelium

Lamina propria

Muscularis propria

Perivesical soft tissue

Slide 12 · Site of origin versus anatomic extent

OBSERVED SITE

PRIMARY ORGAN

EXTENT OF DISEASE

“Tumor in bladder tissue” is an observation.

“Primary bladder carcinoma” assigns its origin.

“Rectal carcinoma involving bladder” assigns both origin and extension.

Slide 13 · Primary bladder staging has a defined scope

Robbins prints the AJCC 8th-edition pTNM table for primary urinary bladder carcinoma.

Its T categories describe local extent of a bladder-origin tumor.

An extravesical primary invading bladder is staged under the appropriate primary site.

Do not assign a bladder-primary pT category solely because bladder is infiltrated.

Slide 14 · The meaning of “T4” is origin-dependent

Bladder primary → adjacent organ

Adjacent-organ primary → bladder

Bladder-primary T4 includes direct spread from the bladder into specified adjacent structures.

The reverse scenario—an adjacent primary entering bladder—is different.

Document the primary site before selecting a staging framework.

Slide 15 · Naming the lesion in a pathology report

Prefer “carcinoma involving urinary bladder, consistent with [known primary]” when supported.

Specify whether source attribution is definitive or only favored.

Avoid an unsupported label of “primary bladder cancer.”

Origin assignment is a conclusion, not a specimen label.

Slide 16 · Cervical carcinoma extending to bladder

The cervix is explicitly listed as a major contiguous source by Robbins.

Correlation with an established cervical tumor and pelvic imaging is essential.

Morphologic overlap with primary bladder squamous carcinoma may complicate biopsy interpretation.

Original organ

Bladder wall

Contiguous tumor

Schematic of direct extension

Slide 17 · Cervix: Diagnostic reasoning

Compare the bladder lesion with previous cervical pathology when available.

Determine whether radiology shows contiguous cervical-to-bladder extension.

Use targeted ancillary tests only after defining the morphologic question.

PRIOR CERVICAL PATHOLOGY

CONTINUITY ON IMAGING

TARGETED PATHOLOGY REVIEW

Slide 18 · Uterine malignancy involving bladder

The uterus is another adjacent source included.

Endometrial/corpus and other uterine primaries require organ-specific correlation.

A glandular lesion in bladder cannot be assigned uterine origin by appearance alone.

Cervix / uterus

Prostate

Rectum

BLADDER

Slide 19 · Uterus: The site-assignment problem

Record the known uterine tumor histotype and prior pathology.

Ask whether the lesion is continuous with the uterine/pelvic mass.

Compare tumor morphology and immunophenotype only within the clinical context.

ORIGINAL UTERINE TUMOR

PELVIC ANATOMY

BLADDER BIOPSY

Slide 20 · Prostatic carcinoma involving bladder

Prostate is a principal adjacent source in the Robbins description.

Bladder neck/trigone involvement may present as a bladder lesion.

In a male with a suspicious gland-forming tumor, prostatic origin must be considered.

Original organ

Bladder wall

Contiguous tumor

Schematic of direct extension

Slide 21 · Prostate: Origin clues to integrate

Relevant history: Prostate carcinoma, treatment, and disease distribution.

Morphology: Assess for glands or patterns matching known prostate cancer.

Ancillary tests such as PSA/PSAP may support prostatic differentiation; Interpret with controls.

PATIENT HISTORY

HISTOLOGIC COMPARISON

PROSTATE-LINEAGE IHC

Slide 22 · Prostate versus urothelial carcinoma

Axis

Prostate-origin involvement

Primary urothelial carcinoma

History

Known or suspected prostate cancer

Bladder-centered tumor history

Morphology

Can show gland-forming carcinoma

Typically urothelial morphology

Ancillary focus

Prostate-lineage markers

Urothelial-lineage markers

Interpretation

Requires clinical and anatomic fit

Requires bladder-origin evidence

Slide 23 · Rectal carcinoma directly invading bladder

The rectum is explicitly listed among the major adjacent organs.

Continuity may be established radiologically or in a combined resection.

Bladder biopsy can contain colorectal-type adenocarcinoma without proving the route.

Original organ

Bladder wall

Contiguous tumor

Schematic of direct extension

Slide 24 · Colorectal adenocarcinoma: Morphology overlaps

Colorectal carcinoma commonly forms malignant glands.

Primary bladder adenocarcinoma may show highly similar enteric morphology.

Gland formation and mucin are not, by themselves, site-specific.

Enteric morphology ≠ proof of colorectal origin.

Slide 25 · Colorectal source: Integrated evidence

Correlate with colonoscopy and cross-sectional imaging when appropriate.

Compare prior colorectal tissue with the bladder specimen.

Use an IHC panel recognizing overlap with primary bladder adenocarcinoma.

ANATOMIC EVIDENCE

PAIRED MORPHOLOGY

PANEL INTERPRETATION

Slide 26 · Four adjacent sources at a glance

Primary site

Likely diagnostic issue

Most helpful context

Cervix

Squamous-pattern mimic

Cervical tumor / pelvic continuity

Uterus

Glandular-pattern mimic

Prior uterine tumor / pelvis

Prostate

Glandular carcinoma in bladder

Prostatic history / lineage markers

Rectum

Enteric glandular mimic

Colorectal pathology / anatomic continuity

Slide 27 · Systemic lymphoma may involve the bladder

SYSTEMIC LYMPHOMA

BLADDER INVOLVEMENT

LINEAGE + EXTENT

Robbins explicitly includes lymphoma as part of systemic disease.

A bladder lesion need not originate from urinary tract epithelium.

Clinical staging must address systemic distribution and lymphoid classification.

Slide 28 · Lymphoma: A distinct lineage problem

EPITHELIAL NEOPLASM

HEMATOLYMPHOID NEOPLASM

Lymphoid malignancy and carcinoma follow different diagnostic pathways.

Epithelial markers alone cannot establish the nature of all poorly differentiated tumors.

Morphology plus hematolymphoid markers establish the appropriate work-up.

Slide 29 · Systemic versus primary bladder lymphoma

A lymphoma in a bladder biopsy is not automatically a primary bladder lymphoma.

Published series describe both primary bladder cases and systemic involvement.

Clinical distribution and previous lymphoma history determine classification.

Bladder involvement is not equivalent to bladder origin.

Slide 30 · Solid-tumor metastases: Uncommon route

DISTANT PRIMARY

SYSTEMIC DISSEMINATION

BLADDER DEPOSIT

Metastatic dissemination of solid tumors to bladder as very rare.

A noncontiguous bladder deposit is possible in disseminated malignancy.

Correlate all suspected cases with disease distribution and original tumor.

Slide 31 · Reported distant primary sites

Published secondary-bladder series include stomach, breast, lung and cutaneous melanoma.

These are reported possibilities, not a probability table for an individual patient.

Prior malignancy and current distribution guide the shortlist.

Slide 32 · Do not confuse rarity with impossibility

A rare route can still be the correct explanation for an individual biopsy.

Clinical history may radically shift pretest probability.

Atypical histology should prompt comparison with known distant primaries.

Uncommon ≠ excluded

Slide 33 · Retrospective distribution: 282 cases

In one historic pathology series of 282 secondary bladder tumors, colon, prostate, rectum and cervix were leading sites.

Percentages are proportions within that selected secondary-tumor series.

They must not be interpreted as incidence among all bladder neoplasms.

Colon

21%

Prostate

19%

Rectum

12%

Cervix

11%

Percentage of the 282 secondary bladder tumors in this series

Slide 34 · Interpreting small, heterogeneous series

Case mix depends on institution, period and surgical/autopsy inclusion.

Direct invasion and distant spread can be combined in published analyses.

Compare denominators and definitions before contrasting studies.

A reported proportion requires its denominator.

Slide 35 · Clinical presentation: Hematuria

Hematuria is a recognized presentation of bladder tumors, including secondary lesions.

Hematuria alone does not distinguish primary from secondary disease.

The history of an extravesical malignancy should influence evaluation.

Slide 36 · Other urinary manifestations

Irritative voiding complaints or obstructive symptoms may accompany secondary involvement.

Symptom type reflects the bladder region and degree of involvement.

Clinical features are nonspecific and cannot independently establish origin.

Slide 37 · Imaging asks an anatomic question

Is the bladder mass continuous with an adjacent-organ tumor?

Is there a bladder-centered lesion without demonstrable pelvic continuity?

What additional sites of malignancy are involved?

CONTIGUITY

BLADDER LOCATION

SYSTEMIC DISTRIBUTION

Slide 38 · Cystoscopy localizes but does not assign origin

Cystoscopy may identify a mucosal lesion or deformation.

Endoscopic appearance is not a reliable lineage test.

Interpret the sampled lesion alongside pelvic imaging and prior pathology.

An endoscopic “bladder tumor” is an anatomic finding.

Slide 39 · Specimen type changes what can be inferred

Small biopsies may lack surrounding organ interface and full wall orientation.

Specimen

Common strength

Common limitation

Biopsy

Confirms lesional histology

Limited architecture / continuity

TURBT

More tissue and muscle sampling

May still lack original interface

En bloc resection

Potential proof of continuity

Needs careful mapping / orientation

Slide 40 · A practical pathology sequence

First: Identify whether the lesion is epithelial, lymphoid or another lineage.

Second: Characterize morphology and compare previous tumor material.

Third: Choose focused ancillary stains, then reconcile imaging and history.

MORPHOLOGY

SOURCE COMPARISON

CORRELATED TESTING

Slide 41 · Morphology can suggest, not guarantee, origin

Many secondary tumors lack a unique histologic signature.

Adenocarcinoma is a particularly difficult diagnostic category.

Diagnostic confidence rises when morphology matches clinical-anatomic evidence.

Histology is necessary; Context may be decisive.

Slide 42 · The gland-forming differential

PRIMARY BLADDER

SECONDARY PELVIC

OTHER GLANDULAR

Primary bladder adenocarcinoma.

Colorectal adenocarcinoma secondarily involving bladder.

Prostatic or gynecologic primary involving bladder.

Urothelial carcinoma with glandular differentiation in selected cases.

Slide 43 · Why enteric morphology is insufficient

PRIMARY BLADDER ADENOCARCINOMA

COLORECTAL ADENOCARCINOMA IN BLADDER

Both bladder-primary and colorectal adenocarcinoma can show enteric gland formation.

Mucinous and signet-ring features also overlap.

A “looks like colon” impression is not proof of the primary site.

Slide 44 · β-catenin: Pattern rather than simple positive/negative

Nuclear staining favors a colorectal source in the Roy et al. Comparative cohort.

Some primary bladder adenocarcinomas can show focal nuclear expression.

Therefore β-catenin is a supporting observation, not a standalone origin test.

Mainly membrane / cytoplasm

Nuclear accumulation

Original educational schematic; Not a micrograph

Slide 45 · CK7, CK20 and CDX2: Substantial overlap

CK20 and CDX2 expression can occur in both bladder-primary and colorectal adenocarcinomas.

CK7 may add context but cannot resolve all difficult cases.

A full panel and radiologic/endoscopic correlation remain necessary.

A marker identifying intestinal differentiation does not always identify intestinal origin.

Slide 46 · Interpreting the mucosal surroundings

Associated glandular metaplasia can provide useful context for bladder-primary adenocarcinoma.

Biopsies may omit or destroy relevant surface urothelium.

Secondary colorectal carcinoma may colonize the surface and mimic an in situ process.

Slide 47 · Squamous-pattern differential

PRIMARY SQUAMOUS BLADDER CARCINOMA

CERVICAL CARCINOMA INVOLVING BLADDER

A squamous carcinoma in bladder may be primary or extend from a gynecologic site.

The presence of squamous differentiation is not enough to define origin.

Known cervical disease and continuity are crucial context.

Slide 48 · Prostate-lineage tests are hypothesis-driven

Adenocarcinoma in a male bladder specimen may prompt evaluation for prostate origin.

PSA and prostatic acid phosphatase are examples of supportive lineage markers.

Read staining with morphology, history and the laboratory’s validation context.

Slide 49 · Lymphoma work-up differs from carcinoma

Assess lymphoid architecture and cytology.

Use hematolymphoid markers and a subtype-directed panel when indicated.

Clinical hematology evaluation establishes whether disease is systemic.

LYMPHOID MORPHOLOGY

IMMUNOPHENOTYPE

SYSTEMIC ASSESSMENT

Slide 50 · Cytology: The same origin limitation

Malignant cells in urine indicate a urinary tract sample containing neoplasia.

Cytology alone may be unable to establish the extravesical primary organ.

Tissue, prior tumor comparison and cross-sectional imaging may be necessary.

Slide 51 · Selecting an immunohistochemical panel

Start with the morphologic differential, not a large indiscriminate stain list.

Ask whether the panel differentiates two plausible tissue origins.

Use multiple convergent findings; Recognize shared marker expression.

DIFFERENTIAL

DISCRIMINATING MARKERS

CLINICAL INTEGRATION

Slide 52 · Why one positive marker is not enough

Many markers reflect differentiation rather than absolute site specificity.

Signal location and distribution can be more informative than binary positivity.

Discordant stains require reconsideration rather than forced classification.

Specificity depends on the diagnostic setting.

Slide 53 · Route-to-diagnosis synthesis

Potential route

Most decisive discriminator

Typical limitation

Direct extension

Demonstrated anatomic continuity

Small biopsy omits interface

Systemic lymphoma

Immunophenotype + systemic work-up

Bladder-only sample

Distant deposit

Known distant malignancy + match

No single unique histology

Slide 54 · Integrated diagnostic decision path

Confirm lesion and identify its morphologic lineage.

Search for a neighboring primary and demonstrate or exclude continuity.

If noncontiguous, reconcile systemic history and targeted marker findings.

State origin with the level of certainty the evidence permits.

Bladder specimen contains malignancy

Known adjacent primary + continuity?

Else: Assess systemic disease + IHC

Assign supported origin / uncertainty

Slide 55 · Elements worth documenting in the final report

Anatomic specimen/site and histologic tumor classification.

Known primary and evidence supporting origin attribution.

Extent of bladder wall involvement in the material sampled.

Any uncertainty or recommendation for clinicoradiologic correlation.

Slide 56 · Four recurring diagnostic pitfalls

Calling every malignant bladder biopsy a primary bladder neoplasm.

Treating enteric morphology or CDX2 expression as origin-specific.

Ignoring prior pelvic malignancy or cross-sectional imaging.

Applying the bladder-primary staging table to an adjacent-organ primary.

Slide 57 · Case 1 — A rectal mass and bladder glands

Diagnostic problem

Patient with a known rectal adenocarcinoma develops a posterior bladder lesion.

Bladder tissue contains infiltrating adenocarcinoma with enteric morphology.

Imaging suggests a continuous mass between rectum and bladder.

What is the most defensible working diagnosis?

Slide 58 · Case 1 — Interpretation

Reasoned resolution

Favor rectal carcinoma involving bladder by direct extension.

The imaging continuity provides evidence beyond enteric histology.

Compare prior rectal tissue and report the primary origin explicitly.

Slide 59 · Case 2 — Prostate history, bladder-neck mass

Diagnostic problem

A man previously treated for prostatic carcinoma develops a bladder-neck lesion.

Biopsy contains infiltrating glands; Mucosal findings are not defining.

Which observations would separate prostatic involvement from bladder primary?

Slide 60 · Case 2 — Interpretation

Reasoned resolution

Review previous prostate tumor and current imaging of bladder neck/prostate.

Apply an appropriate lineage-focused immunostain panel.

Avoid assigning a bladder-primary stage without evidence of bladder origin.

Slide 61 · Case 3 — Bladder lesion in systemic lymphoma

Diagnostic problem

A patient with established systemic lymphoma has a new bladder mass.

Tissue is predominantly composed of atypical lymphoid cells.

What question takes priority over urothelial tumor grading?

Slide 62 · Case 3 — Interpretation

Reasoned resolution

Determine hematolymphoid lineage and lymphoma subtype.

Compare with the established systemic lymphoma.

Classify the lesion as systemic involvement if supported by distribution/history.

Slide 63 · Case 4 — A distant primary with a bladder lesion

Diagnostic problem

A patient with metastatic gastric carcinoma develops an isolated-appearing bladder nodule.

The biopsy demonstrates adenocarcinoma.

Does the biopsy alone establish a new bladder primary?

Slide 64 · Case 4 — Interpretation

Reasoned resolution

No: Metastatic gastric carcinoma is a documented, though unusual, possibility.

Compare original tumor, imaging distribution and the complete immunophenotype.

Classify only when the combined evidence supports the site of origin.

Slide 65 · Diagnostic synthesis

The predominant form of secondary bladder involvement is contiguous extension.

Cervix, uterus, prostate and rectum are the principal adjacent sources.

Systemic lymphoma and rare distant solid-tumor deposits broaden the differential.

Origin attribution requires anatomic, morphologic and clinical integration.

Slide 66 · Final diagnostic checklist

Is there a known or suspected extravesical primary malignancy?

Does imaging demonstrate anatomical continuity with an adjacent tumor?

Does the bladder lesion match previous tumor morphology?

Are targeted markers interpreted with their site-specific limitations?

Does the final diagnosis communicate the supported site of origin?

Slide 67 · Selected references

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026).

Bates AW, Baithun SI. Histopathology. 2000;36:32–40. PMID 10632749.

Roy S et al. Diagn Pathol. 2012;7:151. doi:10.1186/1746-1596-7-151.

Wang L et al. Int J Clin Exp Pathol. 2018;11:5581–5591. PMID 31949645.

El-Taji O et al. Transl Androl Urol. 2021;10:2427–2434. PMID 34295729.

Bates AW et al. J Clin Pathol. 2000. PMID 10911804.